Cytokinetics (CYTK) Completes Phase IIa of CK-2017357
4:01 pm ET 06/02/2011 - StreetInsider
Cytokinetics, Incorporated (Nasdaq: CYTK) has successfully completed its Phase IIa "Evidence of Effect" clinical trial of CK-2017357, a fast skeletal muscle activator, in patients with claudication associated with peripheral artery disease.
Results were presented at the 22nd Annual Sessions of the Society for Vascular Medicine.
A poster titled "A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover Pharmacokinetic and Pharmacodynamic Study of CK-2017357, a Fast Skeletal Muscle Troponin Activator, in Patients with Claudication" was presented by Alan Hirsch, MD, Cardiovascular Division and Lillehei Heart Institute, University of Minnesota, on June 2, 2011.
This poster summarized the results of a recently completed Phase IIa Evidence of Effect clinical trial in patients with calf muscle claudication associated with peripheral artery disease. The authors concluded that CK-2017357 increased calf muscle performance in these patients as evidenced by an increase in work achieved during bilateral heel raise testing, a performance measure in this patient population developed for this trial and presented by Dr. Hirsch in a second poster described below. The authors also concluded that increases in calf muscle performance and adverse events appear related to both increasing dose and to the plasma concentration of CK-2017357. |
